Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02665637 · ClinicalTrials.gov registry record · Phase 1
Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin
A Phase 1 study, sponsored by Celltrion.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT02665637 is a Phase 1 study that has completed, run by Celltrion. The registered enrollment target is 70 participants.
The verdict
NCT02665637, a Phase 1 study, has completed, sponsored by Celltrion.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is a double-blind, two-arm, parallel-group, single-dose study.
Interventions
- DRUG Trastuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02665637
The ClinicalTrials.gov registry entry for NCT02665637 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celltrion, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trastuzumab is the first listed.
NCT02665637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02665637 about?
NCT02665637 is a clinical study titled "Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin". This is a double-blind, two-arm, parallel-group, single-dose study.
What is the current status of trial NCT02665637?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2015-12. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02665637?
The interventions under investigation include: Trastuzumab (DRUG).
Who is sponsoring clinical trial NCT02665637?
This trial is sponsored by Celltrion, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.